You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Expert panel clears Bharat Biotech's vaccine for restricted emergency use

This comes a day after giving similar direction for the Oxford Covid-19 vaccine

Topics
CDSCO | Bharat Biotech | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Representational image of Covaxin

An expert panel of India's central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed COVID-19 vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford COVID-19 vaccine, sources said.

Covaxin has been indigenously developed by in collaboration with the Indian Council of Medical Research (ICMR).

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Saturday again deliberated on the emergency use authorisation (EUA) application of the Hyderabad-based pharmaceutical firm after it submitted additional data, facts and analysis subsequent to Friday's review meeting, a source said.

had applied to the Drugs Controller General Of India (DCGI) seeking emergency use authorisation for its Covaxin on December 7.

On Friday, the SEC had recommended granting permission for restricted emergency use of Oxford-AstraZeneca vaccine Covishield, being manufactured by the Serum Institute of India. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, January 02 2021. 19:06 IST
RECOMMENDED FOR YOU